Drug Costs < Drug Delivery Systems < Drug Design

Facettes : Author.f AffPays.f AffRegion.f AffVille.f AffOrg.f KwdFr.f Mesh.f MeshFr.f Teeft.f

List of bibliographic references indexed by Drug Delivery Systems

Number of relevant bibliographic references: 14.

Ident.	Authors (with country if any)	Title
001478 (2018)	Xavier M. Teitsma [Pays-Bas] ; Wei Yang [Pays-Bas] ; Johannes W G. Jacobs [Pays-Bas] ; Attila Pethö-Schramm [Suisse] ; Michelle E A. Borm [Pays-Bas] ; Amy C. Harms [Pays-Bas] ; Thomas Hankemeier [Pays-Bas] ; Jacob M. Van Laar [Pays-Bas] ; Johannes W J. Bijlsma [Pays-Bas] ; Floris P J G. Lafeber [Pays-Bas]	Baseline metabolic profiles of early rheumatoid arthritis patients achieving sustained drug-free remission after initiating treat-to-target tocilizumab, methotrexate, or the combination: insights from systems biology.
001B01 (2016)	M. Philippart [Pays-Bas] ; J. Schmidt [Suisse] ; B. Bittner [Suisse]	Oral Delivery of Therapeutic Proteins and Peptides: An Overview of Current Technologies and Recommendations for Bridging from Approved Intravenous or Subcutaneous Administration to Novel Oral Regimens.
001B71 (2016)	Paul M. Ridker [États-Unis]	From C-Reactive Protein to Interleukin-6 to Interleukin-1: Moving Upstream To Identify Novel Targets for Atheroprotection.
001B76 (2016)	Gary D. Novack [États-Unis]	Eyes on New Product Development.
002461 (2014)	Yasuharu Nakashima [Japon] ; Masakazu Kondo [Japon] ; Hisaaki Miyahara [Japon] ; Yukihide Iwamoto [Japon]	Drug delivery options to increase patient adherence and satisfaction in the management of rheumatoid arthritis -- focus on subcutaneous tocilizumab.
003431 (2012)	Toshio Tanaka [Japon] ; Masashi Narazaki ; Tadamitsu Kishimoto	Therapeutic targeting of the interleukin-6 receptor.
003496 (2012)	Fernando Kemta Lekpa [France] ; Cécile Poulain [France] ; Daniel Wendling [France] ; Martin Soubrier [France] ; Michel De Bandt [France] ; Jean Marie Berthelot [France] ; Philippe Gaudin [France] ; Eric Toussirot [France] ; Philippe Goupille [France] ; Thao Pham [France] ; Jérémie Sellam [France] ; Rémy Bruckert [France] ; Muriel Paul [France] ; Valérie Farrenq [France] ; Pascal Claudepierre [France]	Is IL-6 an appropriate target to treat spondyloarthritis patients refractory to anti-TNF therapy? a multicentre retrospective observational study
003C45 (2010)	M A Febbraio [Australie] ; S. Rose-John ; B K Pedersen	Is interleukin-6 receptor blockade the Holy Grail for inflammatory diseases?
003C47 (2010)	Aarat M. Patel [États-Unis] ; Larry W. Moreland	Interleukin-6 inhibition for treatment of rheumatoid arthritis: a review of tocilizumab therapy.
003E87 (2009)	Robert J. Moots [Royaume-Uni] ; Andrew Jk Ostör ; John D. Isaacs	Will treatment of rheumatoid arthritis with an IL-6R inhibitor help facilitate the 'age of remission'?
003E99 (2009)	Changhai Ding [Australie] ; Flavia Cicuttini ; Jun Li ; Graeme Jones	Targeting IL-6 in the treatment of inflammatory and autoimmune diseases.
003F09 (2009)	Michael T. Nurmohamed [Pays-Bas]	Newer biological agents in the treatment of rheumatoid arthritis: do the benefits outweigh the risks?
004177 (2007)	Anu Dham [États-Unis] ; Bruce A. Peterson	Castleman disease.
004230 (2006)	Marcus D. Köller [Autriche]	Targeted therapy in rheumatoid arthritis

---

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/TocilizumabV1/Data/Main/Exploration

HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/Mesh.i -k "Drug Delivery Systems" 

HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/Mesh.i  \
                -Sk "Drug Delivery Systems" \
         | HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd 

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    TocilizumabV1
   |flux=    Main
   |étape=   Exploration
   |type=    indexItem
   |index=    Mesh.i
   |clé=    Drug Delivery Systems
}}

---

This area was generated with Dilib version V0.6.34. Data generation: Fri May 22 09:34:00 2020. Site generation: Sun Mar 28 09:01:19 2021